Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

domized, double-blind, placebo-controlled, dose-ranging trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care.  A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)...  Over 100 million adults suffer from chronic pain ... daily. Chronic and acute pain dramatically impacts quality of ... fulfill the need for non-surgical, interventional solutions and medication ... On October 28th, a new pain management center opened ... community.  This new facility boasts cutting edge technologies ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
... Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.,today ... trial of,KW-3902, an adenosine A1 receptor antagonist in ... heart failure (CHF),that indicate a strong trend toward ... KW-3902 experienced a higher rate of,improvement in dyspnea, ...
... Results Presented at the 12th Congress of ... 11, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... EHA in Vienna, Austria, showed positive responses ...
Cached Medicine Technology:Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5
(Date:11/27/2014)... (PRWEB) November 27, 2014 Tylenol lawsuits ... were allegedly injured by the medication are continuing to ... litigation is looking ahead to a status conference in ... a Scheduling Order issued earlier this year, a conference ... 16th at 10:00 a.m. Items likely to be discussed ...
(Date:11/27/2014)... November 27, 2014 “LAB.C” was featured on ... the latest and coolest technology products available to consumers. Mallory ... product review and shared with viewers the company ... and Android devices. , Consumers love portability and functionality. ... Cable Case for the iPhone5 and 5S has a portable ...
(Date:11/27/2014)... HealthPostures, a leading national ... has announced that it has entered into a ... partnership will put HealthPostures' products into central Indiana’s ... addition to having its products sold through Commercial ... products with the business decision makers in the ...
(Date:11/27/2014)... Marietta, GA (PRWEB) November 27, 2014 "The ... the whole month of December is full of laughter as ... Tandy Wilson won by making a sweater from scratch. " ... lit Christmas tree, and if that weren't ridiculous enough, the ... on top. , For those interested in participating this ...
(Date:11/27/2014)... Delhi, India (PRWEB) November 27, 2014 Ethane ... has announced it will provide a 10% Christmas discount on ... month of December. The discount offer will begin on 1 ... 2014. , About this offer, a PPC professional working ... for all, especially for small businesses, as this big discount ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... problem drinkers using alcohol to cope with personal problems ... drinking into adulthood, a recent study suggests. , The ... are still high-risk drinkers by age 34 may have ... development that typically occurs during college, including the ability ...
... 24 Conseco, Inc. (NYSE: CNO ) ... existing $911.8 million senior secured credit agreement. Banc ... in connection with the amendment. The amendment, which ... in the current repayment schedule, is expected to provide ...
... "Hangin, Out With My Baby," ... with their newborns, infants and toddlers, will be distributed free ... hospitals throughout the U.S. Starting today with a live concert ... CDs will be given away this year by participating hospitals.Arranged ...
... Cancer Society Cancer Action Network, the American Heart Association, ... Kids applaud Senator Frank Lautenberg of New Jersey,s call ... authority and immediately remove e-cigarettes from the market. ... publications during the past few weeks saying that e-cigarettes ...
... help metropolitan public health agencies,prepare to deliver essential ... or natural disease outbreak has succeeded in improving,the ... Corporation study. , Researchers found that the federal ... areas, appears to have improved,agencies, ability to rapidly ...
... experts at The University of Nottingham have shown that ... the quality of life for many community-based dialysis patients. ... journal Biomaterials , have shown that the catheter ... wider variety of pathogens and protect Continuous Ambulatory Peritoneal ...
Cached Medicine News:Health News:Study helps identify college drinkers who might continue excessive drinking as adults 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 3Health News:Study helps identify college drinkers who might continue excessive drinking as adults 4Health News:Study helps identify college drinkers who might continue excessive drinking as adults 5Health News:Conseco Seeks Amendment of Its Credit Facility 2Health News:Conseco Seeks Amendment of Its Credit Facility 3Health News:Conseco Seeks Amendment of Its Credit Facility 4Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 2Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 3Health News:Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids 2Health News:Study finds program has improved health agencies' preparedness for bioterror and disease outbreaks 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 3
... molecular biology grade, standard melting temperature agarose that ... DNA, RNA, and PCR products = 1 kb. ... processing and blotting. Performance testing of NuSieve 3:1 ... to 1,000 bp, though this agarose is capable ...
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
... gel strength, high electrophoretic mobility, and ... is the superior choice for CHEF ... easy to handle at concentrations as ... run times. Low background staining also ...
... general-purpose agarose, like the entire line of ... grade. This ensures that DNA recovered from ... compromising quality. Certified molecular biology agarose is ... molecular weight, resulting in a gel structure ...
Medicine Products: